A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Net neutrality === Pritzker supports net neutrality, and wrote on his gubernatorial campaign website: "As governor, I will ensure that all internet traffic is treated equally, so that everyone can continue to use the internet to grow their businesses, further their education, and enjoy the freedom of expression."
=== Political control === The council has been under Reform UK majority control since the 2025 election. Durham was the first county council to be controlled by Labour, who took power in 1919. Between 1922 and 1925, the council was under no overall control with a Labour minority administration. From 1925 until 2021, Labour held a majority. Political control since 1919 has been as follows:
The executive branch of government is responsible for managing the defense of Colombia, with the President commander-in-chief of the armed forces. The Ministry of Defence exercises day-to-day control of the military and the Colombian National Police. Colombia has 455,461 active military personnel. In 2016, 3.4% of the country's GDP went towards military expenditure, placing it 24th in the world. Colombia's armed forces are the largest in Latin America, and it is the second largest spender on its military after Brazil. In 2018, Colombia signed the UN treaty on the Prohibition of Nuclear Weapons. The Colombian military is divided into three branches: the National Army of Colombia; the Colombian Aerospace Force; and the Colombian Navy. The National Police functions as a gendarmerie, operating independently from the military as the law enforcement agency for the entire country. Each of these operates with their own intelligence apparatus separate from the National Intelligence Directorate (DNI, in Spanish). The National Army is formed by divisions, brigades, special brigades, and special units, the Colombian Navy by the Naval Infantry, the Naval Force of the Caribbean, the Naval Force of the Pacific, the Naval Force of the South, the Naval Force of the East, Colombia Coast Guards, Naval Aviation, and the Specific Command of San Andres y Providencia and the Aerospace Force by 15 air units.
Sources: en.wikipedia.org
Its objectives include comparison of survival, cardiovascular mortality and morbidity, pharmacological activity (e.g., suppression of testosterone levels), other side effects and toxicities, and quality of life. In addition to the PATCH trial, the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) study added a high-dose estradiol patches arm (~2,000 men) in July 2017. Estradiol patches are associated with local skin reactions and such as irritation in 14.2% of individuals (with reservoir patches), mild-to-moderate erythema (redness) in 50 to 60% of individuals, and allergic reactions due to cutaneous sensitization. Up to 5% of people using reservoir patches may discontinue therapy due to skin reactions. Visible adhesive residues are also often left by estradiol patches following their removal. Transdermal estradiol gel can serve as an alternative to transdermal estradiol patches for individuals who experience intolerable skin reactions with them. Estradiol patches should not be applied to the breast as this may result in high local levels of estradiol in the breasts and hence an increased likelihood of breast tenderness.
=== Metabolism and body weight === As of 2017, reviews of clinical trials showed that using aspartame (or other non-nutritive sweeteners) in place of sugar reduces calorie intake and body weight in adults and children. A 2017 review of metabolic effects by consuming aspartame found that it did not affect blood glucose, insulin, total cholesterol, triglycerides, calorie intake, or body weight. While high-density lipoprotein levels were higher compared to control, they were lower compared to sucrose. In 2023, the World Health Organization recommended against the use of common non-sugar sweeteners (NSS), including aspartame, to control body weight or lower the risk of non-communicable diseases, stating: "The recommendation is based on the findings of a systematic review of the available evidence which suggests that use of NSS does not confer any long-term benefit in reducing body fat in adults or children. Results of the review also suggest that there may be potential undesirable effects from long-term use of NSS, such as an increased risk of type 2 diabetes, cardiovascular diseases, and mortality in adults."
By September 1900, the British were nominally in control of both Republics, with the exception of north Transvaal. However, they discovered they only controlled the territory their columns physically occupied. Despite the loss of their capitals and half their army, the Boer commanders adopted guerrilla warfare, conducting raids against railways, resource and supply targets, aimed at disrupting the operational capacity of the British Army. They avoided pitched battles and casualties were light. Boer commando units were sent to the district from which its members were recruited, which meant they could rely on local support and knowledge of the terrain and towns, enabling them to live off the land. Their orders were simply to act against the British whenever possible. Their tactics were to strike fast causing as much damage as possible, then withdraw before enemy reinforcements could arrive. The vast distances of the republics allowed Boer commandos freedom to move about and made it nearly impossible for the 250,000 British troops to control the territory effectively using columns alone. As soon as a British column left a town or district, British control of that area faded away. Boer commandos were especially effective during the initial guerrilla phase because Roberts had assumed the war would end with the capture of the capitals and dispersal of the Boer armies. British troops were therefore redeployed out of the area, and had been replaced by lower-quality Imperial Yeomanry and locally-raised irregular corps.
== Applications == LbL has found applications in protein purification, corrosion control, (photo)electrocatalysis, biomedical applications, ultrastrong materials, and many more. LbL composites from graphene oxide harbingered the appearance of numerous graphene and graphene oxide composites later on. The first use of reduced graphene oxide composites for lithium batteries was also demonstrated with LbL multilayers.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.